Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study
J. Medina, Emeric Chassaing, Griselda Ballering, et al.
The Lancet Infectious Diseases (2021) Vol. 21, Iss. 8, pp. 1141-1150
Closed Access | Times Cited: 18

Showing 18 citing articles:

Identification of highly conserved Trypanosoma cruzi antigens for the development of a universal serological diagnostic assay
Alicia Majeau, Eric Dumonteil, Claudia Herrera
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 9
The Trypanosoma cruzi Antigen and Epitope Atlas: antibody specificities in Chagas disease patients across the Americas
Alejandro D. Ricci, Leonel Bracco, Emir Salas‐Sarduy, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2–Naive Residents of Nursing Homes
Pieter Pannus, Kristof Y. Neven, Stéphane De Craeye, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e695-e704
Open Access | Times Cited: 30
Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults
Nicolás Falk, Ariel Berenstein, Guillermo Moscatelli, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 5
Open Access | Times Cited: 19
ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment
Rocío Rivero, Mónica I. Esteva, Erya Huang, et al.
PLoS neglected tropical diseases (2023) Vol. 17, Iss. 6, pp. e0011440-e0011440
Open Access | Times Cited: 6
Assessing antibody decline after chemotherapy of early chronic Chagas disease patients
Niamh Murphy, Marta Victoria Cardinal, Tapan Bhattacharyya, et al.
Parasites & Vectors (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure
Amanda Fortes Francisco, Ursula Saade, Shiromani Jayawardhana, et al.
PLoS neglected tropical diseases (2022) Vol. 16, Iss. 10, pp. e0010827-e0010827
Open Access | Times Cited: 9
Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins
Tycha Bianca Sabaini Pavan, Leonardo Maia Leony, Wayner Vieira de Souza, et al.
Folia Parasitologica (2024) Vol. 71
Open Access | Times Cited: 1
Chagas disease treatment efficacy markers: experiences from a Phase III study with nifurtimox in children
Ulrike Grossmann, María-Luisa Rodríguez
Frontiers in Parasitology (2023) Vol. 2
Open Access | Times Cited: 3
A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections
Lola Marqué, Peter Liehl, Jasper de Boer, et al.
PLoS neglected tropical diseases (2021) Vol. 15, Iss. 11, pp. e0009925-e0009925
Open Access | Times Cited: 6
Considerações sobre o tratamento etiológico da doença de chagas e critério de cura
Ana Laura Miranda Campanha, Ana Carolina Lima Barros, Daiane Aparecida Soares de Sousa, et al.
Revista Eletrônica Acervo Médico (2023) Vol. 23, Iss. 7, pp. e12925-e12925
Open Access | Times Cited: 2
An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study
Manuel Abal, Virginia Balouz, Rosana López, et al.
PLoS neglected tropical diseases (2024) Vol. 18, Iss. 1, pp. e0011910-e0011910
Open Access
Congenital transmission of Chagas disease: The role of newborn therapy on the disease’s dynamics
Meriem Boukaabar, Bismark Oduro, Paul Chataa
PLoS ONE (2024) Vol. 19, Iss. 9, pp. e0308136-e0308136
Open Access
Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay
Ursula Saade, Jasper de Boer, Ivan Scandale, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access
Congenital transmission of Chagas disease: The role of newborn therapy on the disease’s dynamics
Meriem Boukaabar, Bismark Oduro, Paul Chataa
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
An end is in sight: a perspective on PCR as an endpoint for Chagas disease treatment trials
Natasha S. Hochberg, Srinivasa P. S. Rao, Gerhild Angyalosi, et al.
Frontiers in Parasitology (2023) Vol. 2
Open Access
A Trypanosoma cruzi Antigen and Epitope Atlas: deep characterization of antibody specificities in Chagas Disease patients across the Americas
Alejandro D. Ricci, Leonel Bracco, Janine M. Ramsey, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Closed Access
Parasitological cure in children infected with Trypanosoma cruzi
Leonardo Maia Leony, Fred Luciano Neves Santos
The Lancet Infectious Diseases (2021) Vol. 21, Iss. 8, pp. 1058-1059
Closed Access
Page 1

Scroll to top